FluidSmart TM ) improves procedural efficiency and nurse and surgeon satisfaction regarding irrigation during percutaneous nephrolithotomy.
INTRODUCTION AND OBJECTIVES: Ureteral stents relieve obstruction and maintain renal drainage. However, chronic indwelling stents carry complications including fragmentation, migration, and encrustation. Other than indwelling time, factors contributing to stent encrustation are unknown. A donor urine bath model for studying stent encrustation has previously been presented. The purpose of this study is to compare the risk for encrustation and force required for removal in soft, firm, multi-length, and fixed length stents in a controlled artificial urine bath.
METHODS: Twenty-four double pigtail stent coils (6 firm multilength, 6 soft multi-length soft, 6 firm fixed length, 6 soft fixed length stent coils) were bathed in an in vitro artificial urine solution to simulate a rapid encrustation model. The stents were bathed for 15 days in an incubator at human body temperature. The urine bath was exchanged every 3 days and the length and diameter of the stent coils were measured. The force required for stent extraction from a ureteral benchtop model was measured in newtons (N) using a force gauge before and after the urine bath. Mann-Whitney U test was used for statistical analysis with p<0.05 considered significant. RESULTS: After 15 days, all stents showed evidence of encrustation on gross evaluation and scanning electron microscopy. The mean force required for stent removal after the urine bath was 0.664 N (firm fixed), 0.549N (firm multi), 0.502N (soft fixed), 0.475N (soft multi). Firm stents required significantly more force for removal than soft stents prior to the urine bath (0.290N vs 0.162N respectively; p<0.001) and after the urine bath (0.606N vs 0.488N respectively; p[0.01) regardless of whether these stents were fixed or multi-length. Soft stents increased in both length (9.5 to 12.7 cm; p<0.001) and diameter (1.4 to 3.3 mm; p<0.001) while firm stents only increased in diameter (1.4 to 2.3 mm; p<0.001).
CONCLUSIONS: This benchtop study validates an artificial urine bath as a model for studying stent encrustation. Signs of stent encrustation occurred as early as 15 days. While firm stents required more force for removal, soft stents demonstrated significant spatial changes in vitro. These should be considered at the time of stent selection to optimize patient comfort and quality of life. INTRODUCTION AND OBJECTIVES: Percutaneous Nephrolithotomy (PCNL) has been widely performed procedure for the management renal stones. Standard PCNL is usually performed through 24-to 30-Fr percutaneous tracts. Several reports have suggested that the risk of bleeding is associated with Amplatz sheath size. To decrease the morbidity related to larger tracts such as bleeding, postoperative pain, and potential renal damage; modifications to the size of the instruments have been made. The miniature version of mini PCNL i.e., Mini Micro PCNL(MMP) using 8.5/9.5F sheath and 7.5Fr nephroscope has been developed for the treatment of renal calculi of size 1-2cm. We intend to validate the safety, efficacy, and applicability of Mini-Micro PCNL in our study.
METHODS: We prospectively evaluated the outcomes of MiniMicro PCNL in a single surgeon, single center study. Data of 40 patients who underwent Mini-Micro PCNL from May 2016 to December 2017 were evaluated. Patients were assessed on 1st month and at 3rd month postoperatively by X ray/ CT KUB to assess stone free status.
RESULTS: The mean age of the patients was 43.43 years (20-77 years). The mean BMI was 28.3 Kg/m2. The Mean stone size was 15.13 mm. 22 patients had calculus size of 1.2e1.5 cm, 18 patients had calculus size of 1.6e 2 cm. The position of the calculus were in upper calyx (N[ 2), middle calyx (N[ 5), lower calyx (N[ 9), pelvic (N[20) and pelvi-ureteric junction (N[4) . Access was achieved through superior calyx (N[ 19) middle (N[ 13) and lower (N[13) . The Mean operative time (the puncture of kidney to removal of outer sheath after completion of fragmentation) was 40.48 mins (Range 17e70 mins). Mean haemoglobin loss was 0.663 gm /dl. Mean creatinine increase was 0.07 mg/dl. There were no blood transfusions. Grade 1 Clavein Dindo complication i.e., fever was seen in 7 cases. 5 patients had low grade fever (99-100F) for 6-8hrs, 2 patients had moderate fever (100-103F). Post operatively single dose, parental analgesia i.e., aqueous diclofenac 75 mg was given in the early hours post operatively (0-4 hours) in 82.5% patients after measuring pain statically and dynamically. Mean length of hospital stay was 36.35 hours (Range 25e84 hours). DJ stenting was done in all patients which was removed after 1 month. Stone free rate was 90% at 1st month, 100% at 3rd month postoperatively.
CONCLUSIONS: Mini-Micro PCNL is a safe and efficacious technique in the management of renal calculi of size < 2 cm. This procedure can be recommended as it gives excellent stone free status, reduced analgesic requirements, early post op recovery and is cost effective.
Source of Funding: None

MP17-20 A COMPARISON OF PATIENT DESIRED OUTCOMES BETWEEN PAIN AND NON-PAIN-FOCUSED PATIENTS FOLLOWING NEPHROLITHIASIS SURGERY
Nicholas B. Koch*, Elaine K. Kearney, Catherine Wiener, Gary G. Koch, Leslie D. Lorbacher, Davis Viprakasit, Chapel Hill, NC INTRODUCTION AND OBJECTIVES: Renal colic is one of the most common and concerning complaints for patients with symptomatic kidney stones. The patient perspective historically has not been considered in the evaluation of treatment outcomes in kidney stone surgery. The Patient Centered Outcomes Questionnaire is a validated tool developed for the investigation of patient perspectives in chronic pain. Using a modified PCOQ, we investigated the difference in patient defined outcomes in pain and non-pain focused patients following stone surgery.
METHODS: 59 symptomatic patients undergoing either ureteroscopic or percutaneous stone surgery participated in a longitudinal assessment by completing a modified, stone-specific Patient Centered Outcomes Questionnaire (sPCOQ) prior to surgery and at their routine postoperative follow-up. Patients' expected, desired, and success levels of pain symptoms following surgery were determined. Responses were then compared between pain-focused and non-painfocused patient subgroups as defined by patients' determination of importance of pain control.
RESULTS: The cohort was 68% female and had a mean age of 54.9 years. A positive stone history was reported in 69% and was significantly higher in the pain-focused population. Pain-focused patients required a larger reduction in symptoms to meet their outcome criteria for desired, expected, and success levels though these defined levels were all relatively similar. Non-pain focused patients also desired the greatest reduction in pain. However, these patients expected and would accept lower levels of improvement in symptoms to consider treatment successful. Overall, all patients had a significant improvement in pain symptoms following surgery. However, patients who rated pain as their primary criteria for success were significantly less likely to reach their expected outcome level for pain (p<0.05) and overall, pain-focused patients were less likely to meet their defined success criteria.
CONCLUSIONS: The sPCOQ provides a valuable tool in assessing patient perspectives in treatment outcomes for pain symptoms in kidney stone patients undergoing surgery. Pain-focused patients have stricter criteria for their desired, expected, and successful outcomes following kidney stone surgery. Additionally, they may elevate all outcome criteria more similarly to their desired levels. As a result, these patients may be less likely to reach their treatment goals. This suggests kidney stone patients with a predominant pain complaint could require more attention and counseling regarding treatment outcomes and realistic expectation management following surgery. 
INTRODUCTION AND OBJECTIVES:
The correlation between PCa and increased levels of the most important androgens is well known. The aim of the present study was to evaluate prostate cancer (PCa)-induced deviation of a limited endogenous androgenic anabolic steroids (EAAS) profile on urine samples. METHODS: The current study enrolled 283 patients: 139 "healthy subjects" or control group (w49%) (PSA 4 ng/mL or PSA > 4 with at least one negative biopsy), and 144 (w51%) individuals affected by PCa histologically proved. The individuals affected by diabetes, other carcinoma, metabolic diseases, subjected to steroidal therapy or other kind of therapy suspected to alter the urinal steroid profile (USP), i.e. anti-hypercholesterolemia treatments, were not included in the study. All samples were collected in the morning.
Two multivariate classification models based on the partial least square discriminant analysis (PLS-DA) algorithm were built (in cross validation, using the venetian blind strategy and 5 deletion groups) employing the training set: model 1 including three urinary steroids (Testosterone, Etiocholanolone and 7b-OH-DHEA) based on the methodology of gas chromatography e mass spectrometry (GC/MS) þ PSA and model 2 including only USP. The performances of the models were evaluated using the test set.
RESULTS: PLS-DA models built using the 3 steroids and PSA (model 1) and only the USP selected variables (model 2) are reported in Figure 1 . Sensibility, specificity and Area Under the Curve of the ROC analysis for model 1 and model 2, were: 83%, 84%, 0.93 and 88%, 79%, 0.89, respectively.
CONCLUSIONS: This study can confirm the effectiveness of a limited and cheap USP in PCa diagnosis and the possible activation of anomalous steroid biosynthesis induced from cancer cells.
